Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Tina C. Lavranos"'
Autor:
Bernard Flynn, Clayton A. Matthews, Michael O'Callaghan, Allison Hall, Jelena Gasic, Donna Beaumont, Tina C. Lavranos, Annabell F. Leske, Gabriel Kremmidiotis
Vascular disruption agents (VDA) cause occlusion of tumor vasculature, resulting in hypoxia-driven tumor cell necrosis. Tumor vascular disruption is a therapeutic strategy of great potential; however, VDAs currently under development display a narrow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87b4d9f87ffff55b4fc8503c2bba2862
https://doi.org/10.1158/1535-7163.c.6531642.v1
https://doi.org/10.1158/1535-7163.c.6531642.v1
Autor:
Bernard Flynn, Clayton A. Matthews, Michael O'Callaghan, Allison Hall, Jelena Gasic, Donna Beaumont, Tina C. Lavranos, Annabell F. Leske, Gabriel Kremmidiotis
Adobe PDF - Supplementary_Data.pdf from BNC105: A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99dbc5fd464c1e0c22a679fb4777ae08
https://doi.org/10.1158/1535-7163.22484895.v1
https://doi.org/10.1158/1535-7163.22484895.v1
Autor:
Daniel J. Inglis, Katharina Winkler, Tina C. Lavranos, Marnie Winter, Zhen Cai, Kristen Georgiou, Meysam Rezaei, Benjamin Thierry, Majid Ebrahimi Warkiani
Publikováno v:
MethodsX, Vol 6, Iss, Pp 1512-1520 (2019)
The detection and molecular analysis of circulating tumour cells (CTCs) potentially provides a significant insight to the characterisation of disease, stage of progression and therapeutic options for cancer patients. Following on from the protocol by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::797f1db6b86a0fe402ea67ef144c550a
http://www.sciencedirect.com/science/article/pii/S2215016119301694
http://www.sciencedirect.com/science/article/pii/S2215016119301694
Autor:
Katherine L. Morel, Tina C Lavranos, Sonja Klebe, David J. Elliot, Linh Tran, Karen M. Lower, Rebecca J. Ormsby, Pamela J. Sykes, Ganessan Kichenadasse
Publikováno v:
In Vivo. 33:99-108
Background/aim The hypoglycemic drug metformin (MET) and the anti-epileptic drug valproic acid (VPA) have individually shown anti-tumor effects in prostate cancer in vitro. The present study intended to investigate the efficacy of the combination of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1b8bdd9e7e9091719c10eef20df1485
https://doi.org/10.21873/invivo.11445
https://doi.org/10.21873/invivo.11445
Autor:
Annabell F. Leske, Julie Martyn, Tina C. Lavranos, David Espinoza, Dirkje W. Sommeijer, Jose Iglesias, Philip Beale, Elizabeth E. Doolin, Jeremy Simpson, Danny Rischin, Jeff C. Goh, Gabriel Kremmidiotis, Emma C. Rossi, Kristina Lindemann, Anneso S. Veillard, Martin R. Stockler, Michelle Margaret Vaughan, Meaghan Tenney
Publikováno v:
Cancer chemotherapy and pharmacology, 83(1), 97-105. Springer Verlag
Purpose: The primary objective of this study was to determine the recommended dose of the vascular disrupting agent, BNC105P, in combination with gemcitabine and carboplatin in patients with ovarian cancer in first or second relapse with a minimum 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1505eabd827e65c42487a3157a87ae2b
https://pure.amc.nl/en/publications/phase-i-study-of-bnc105p-carboplatin-and-gemcitabine-in-partially-platinumsensitive-ovarian-cancer-patients-in-first-or-second-relapse-anzgog1103(bec4efc5-2158-432c-b127-5dc2abc25aa3).html
https://pure.amc.nl/en/publications/phase-i-study-of-bnc105p-carboplatin-and-gemcitabine-in-partially-platinumsensitive-ovarian-cancer-patients-in-first-or-second-relapse-anzgog1103(bec4efc5-2158-432c-b127-5dc2abc25aa3).html
Autor:
Linh N K, Tran, Ganessan, Kichenadasse, Katherine L, Morel, Tina C, Lavranos, Sonja, Klebe, Karen M, Lower, Rebecca J, Ormsby, David J, Elliot, Pamela J, Sykes
Publikováno v:
In vivo (Athens, Greece). 33(1)
Background/Aim: The hypoglycemic drug metformin (MET) and the anti-epileptic drug valproic acid (VPA) have individually shown anti-tumor effects in prostate cancer in vitro. The present study intended to investigate the efficacy of the combination of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a43632bd7f4963d96365b0bcc327bcc6
https://pubmed.ncbi.nlm.nih.gov/30587609
https://pubmed.ncbi.nlm.nih.gov/30587609
Autor:
Daniel J. Inglis, Chloe K. Brown, Tina C. Lavranos, Gabriel Kremmidiotis, Annabell F. Leske, Allison J Hall, Donna M. Beaumont
Publikováno v:
Cancer Biology & Therapy. 15:1552-1560
BNC105 is a tubulin targeting compound that selectively disrupts vasculature within solid tumors. The severe tumor hypoxia and necrosis that ensues translates to short term tumor growth inhibition. We sought to identify the molecular and cellular eve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a01c1827bb4cbe42fff8f8ee5b023ff
https://doi.org/10.4161/15384047.2014.956605
https://doi.org/10.4161/15384047.2014.956605
Autor:
David K. Chalmers, Jason H. Chaplin, Tina C. Lavranos, Bernard L. Flynn, Annabell F. Leske, Dharam Paul, Gurmit S. Gill, Damian Grobelny, Ernest Hamel, Edmund Kostewicz, Julia Morizzi, M. Katherine Jung, David M. Shackleford, Gabriel Kremmidiotis, Susan A. Charman
Publikováno v:
Journal of Medicinal Chemistry. 54:6014-6027
A structure-activity relationship (SAR) guided design of novel tubulin polymerization inhibitors has resulted in a series of benzo[b]furans with exceptional potency toward cancer cells and activated endothelial cells. The potency of early lead compou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e50248d4cd2d0cae01b413445e930e2a
https://doi.org/10.1021/jm200454y
https://doi.org/10.1021/jm200454y
Autor:
Tran Nguyen, Nicole L Wittwer, Tina C. Lavranos, Donna M. Beaumont, Daniel J. Inglis, David M. Ross, Richard J D'Andrea, Debora A. Casolari
Publikováno v:
Cancer Research. 78:1881-1881
BNC105 is a phase II potent and highly selective disruptor of tumor microvasculature that causes the rapid onset of hypoxia and necrosis in solid tumors. BNC105 targets the colchicine-binding site on tubulin, causing chronic disruption of adhesion mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f78073739375134e5e80c6748a01375f
https://doi.org/10.1158/1538-7445.am2018-1881
https://doi.org/10.1158/1538-7445.am2018-1881
Autor:
Daniel J. Inglis, John Licari, Kristen Georgiou, Ross W. Hamilton, Donna M. Beaumont, Michaela Scherer, Nicole L. Wittwer, Tina C. Lavranos
Publikováno v:
Cancer Research. 78:3910-3910
At the base of normal intestinal crypts, stem cells maintain the highly regenerative gut epithelium. These intestinal stem cells are well characterized for their high expression of the G coupled protein receptor LGR5 (also known as GPR49). Together w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46f38e60121d409879f97c5fbf941cb9
https://doi.org/10.1158/1538-7445.am2018-3910
https://doi.org/10.1158/1538-7445.am2018-3910